CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®. IntelGenx's development partner, Cary Pharma, serves as the NDA ...
With the potential to be the first and only single-tablet high-dose form of bupropion HCl on the market, we believe CPI-300's convenience and patient ...
CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL(R). IntelGenx's development partner, Cary Pharma, serves as the ...
The drug contains Bupropion HCL, which is the “active ingredient” of Welbutrin XL®. The latter has been discovered and patented by the Biovail Laboratories ...
Email this story